Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients
- 19 September 2014
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (4) , 836-846
Abstract
Aims: Ciclosporin A (CsA) is used in the prophylaxis and treatment of acute and chronic graft vs. host disease after haematopoietic stem cell (HSCT) transplantation. Our objective was to build and compare three independent Bayesian estimators of CsA area under the curve (AUC) using a limited sampling strategy (LSS), to assist in dose adjustment.Methods: The Bayesian estimators were developed using in parallel: two independent parametric modelling approaches (nonmem® and iterative two stage (ITS) Bayesian modelling) and the non‐parametric adaptive grid method (Pmetrics®). Seventy‐two full pharmacokinetic profiles (at pre‐dose and 0.33, 0.66, 1, 2, 3, 4, 6, 8 and 12h after dosing) collected from 40 HSCT patients given CsA were used to build the pharmacokinetic models, while 15 other profiles (n = 7) were kept for validation. For each Bayesian estimator, AUCs estimated using the full profiles were compared with AUCs estimated using three samples.Results: The pharmacokinetic profiles were well fitted using a two compartment model with first order elimination, combined with a gamma function for the absorption phase with ITS and Pmetrics or an Erlang distribution with nonmem. The derived Bayesian estimators based on a C0‐C1 h‐C4 h sampling schedule (best LSS) accurately estimated CsA AUC(0,12 h) in the validation group (n = 15; nonmem: bias (mean ± SD)/RMSE 2.05% ± 13.31%/13.02%; ITS: 4.61% ± 10.56%/11.20%; Pmetrics: 0.30% ± 10.12%/10.47%). The dose chosen confronting the three results led to a pertinent dose proposal.Conclusions: The developed Bayesian estimators were all able to predict ciclosporin AUC(0,12 h) in HSCT patients using only three blood with minimal bias and may be combined to increase the reliability of CsA dose adjustment in routine.Keywords
This publication has 21 references indexed in Scilit:
- Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipientEuropean Journal of Clinical Pharmacology, 2012
- Current Practice of Therapeutic Drug Monitoring2012
- Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategyBritish Journal of Clinical Pharmacology, 2011
- A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefitsNephrology Dialysis Transplantation, 2010
- Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5Drug Metabolism and Disposition, 2007
- Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant PatientsClinical Pharmacokinetics, 2006
- A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate MofetilClinical Pharmacokinetics, 2005
- Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantationTransplantation and Cellular Therapy, 2003
- Application of a Gamma Model of Absorption to Oral CyclosporinClinical Pharmacokinetics, 2001
- Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus PanelTherapeutic Drug Monitoring, 1995